Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study ; volume:43 ; number:5 ; day:1 ; month:3 ; year:2023 ; pages:889-902 ; date:5.2023
Rheumatology international ; 43, Heft 5 (1.3.2023), 889-902, 5.2023
- Urheber
-
Sfikakis, Petros P.
Vassilopoulos, Dimitrios
Katsifis, Gkikas
Vosvotekas, Georgios
Dimitroulas, Theodoros
Sidiropoulos, Prodromos
Vounotrypidis, Periklis
Bogdanos, Dimitrios P.
Georgountzos, Athanasios Ι
Bounas, Andreas G.
Georgiou, Panagiotis
Gazi, Souzana
Kataxaki, Evangelia
Liossis, Stamatis-Nick
Theodorou, Evangelos
Papagoras, Charalampos
Theotikos, Evangelos
Vlachoyiannopoulos, Panayiotis
Voulgari, Paraskevi V.
Kekki, Angeliki
Antonakopoulos, Nikolaos
Boumpas, Dimitrios T.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00296-022-05269-z
- URN
-
urn:nbn:de:101:1-2023081909171780511388
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sfikakis, Petros P.
- Vassilopoulos, Dimitrios
- Katsifis, Gkikas
- Vosvotekas, Georgios
- Dimitroulas, Theodoros
- Sidiropoulos, Prodromos
- Vounotrypidis, Periklis
- Bogdanos, Dimitrios P.
- Georgountzos, Athanasios Ι
- Bounas, Andreas G.
- Georgiou, Panagiotis
- Gazi, Souzana
- Kataxaki, Evangelia
- Liossis, Stamatis-Nick
- Theodorou, Evangelos
- Papagoras, Charalampos
- Theotikos, Evangelos
- Vlachoyiannopoulos, Panayiotis
- Voulgari, Paraskevi V.
- Kekki, Angeliki
- Antonakopoulos, Nikolaos
- Boumpas, Dimitrios T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis